Anavex Life Sciences Corp (AVXL)

[powerwalker]

McM, IMO, the issue isn't the base line of Week 0 or Week 5, it is the inability to identify that donepezil turns 2-73 into a neutral/negative drug or, in effect, a placebo in those early weeks.

We don't know all the doseage and level of each participants' bio-markers, so my comments might be out of place.

The fact is that the negativity in practically all data elements is donepezil's effect on 2-73, whether it were in the short term or throughout the 31 weeks.

Something stinks and it is not the "stink bids" from you know who. The PR is extremely inadequate and the interpretation of the data matches the PR. Why wasn't the Week 17 to Week 31 MMSE data for the "2-73 only" group highlighted in the headlines ... it went from <21 to >24 ... and the only remark made is:

Similar MMSE score effect and no notable difference between exploratory analysis of ANAVEX 2-73 alone and ANAVEX 2-73 with donepezil (DPZ).

REALLY! Whereas, the group receiving the combo dropped from ~20 to ~19. [Regardless of the max of 7 participants of "2-73 only", it is what it is and it should have been the featured number ... let the larger trial discredit it if it is to be discredited.]

Again, something stinks! ... and, I go back to my previous question in a post 600+ ago, "This information was delayed why?"